Home Cart 0 Sign in  

[ CAS No. 7764-95-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 7764-95-6
Chemical Structure| 7764-95-6
Structure of 7764-95-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 7764-95-6 ]

Related Doc. of [ 7764-95-6 ]

Alternatived Products of [ 7764-95-6 ]

Product Details of [ 7764-95-6 ]

CAS No. :7764-95-6 MDL No. :MFCD00063123
Formula : C8H15NO4 Boiling Point : -
Linear Structure Formula :- InChI Key :QVHJQCGUWFKTSE-RXMQYKEDSA-N
M.W : 189.21 Pubchem ID :637606
Synonyms :
N-tert-Butoxycarbonyl-D-alanine
Chemical Name :Boc-D-Ala-OH

Calculated chemistry of [ 7764-95-6 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.75
Num. rotatable bonds : 5
Num. H-bond acceptors : 4.0
Num. H-bond donors : 2.0
Molar Refractivity : 46.86
TPSA : 75.63 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.8 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.8
Log Po/w (XLOGP3) : 0.92
Log Po/w (WLOGP) : 0.98
Log Po/w (MLOGP) : 0.51
Log Po/w (SILICOS-IT) : -0.17
Consensus Log Po/w : 0.81

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -1.26
Solubility : 10.3 mg/ml ; 0.0546 mol/l
Class : Very soluble
Log S (Ali) : -2.09
Solubility : 1.52 mg/ml ; 0.00805 mol/l
Class : Soluble
Log S (SILICOS-IT) : -0.64
Solubility : 43.0 mg/ml ; 0.228 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.54

Safety of [ 7764-95-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 7764-95-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 7764-95-6 ]

[ 7764-95-6 ] Synthesis Path-Downstream   1~8

  • 1
  • [ 338-69-2 ]
  • [ 24424-99-5 ]
  • Boc-(R)-Ala [ No CAS ]
YieldReaction ConditionsOperation in experiment
100% Stage #1: D-Alanine With sodium hydroxide In water at 0℃; for 0.166667h; Stage #2: di-<i>tert</i>-butyl dicarbonate In tetrahydrofuran; water at 20℃; 15.1 Step 1: (2R)-2-(tert-butoxycarbonylamino)propanoic acid (17B) [0228] No.28 D-alanine (17A) (10 g, 112.24 mmol) and No.5 water (56 mL) were added in a 250 mL reaction flask, and the reaction solution was cooled to 0°C and then No.5 sodium hydroxide (6.73 g, 168.36 mmol) was added. After the addition, the reaction was held at 0°C for 10 minutes, and then a solution of No.2 di-tert-butyl dicarbonate (31.85 g, 145.91 mmol) in No.2 tetrahydrofuran (50 mL) was added dropwise. After the addition, the temperature was raised to room temperature and stirred overnight. The reaction solution was extracted with petroleum ether (100 mL 2) and the organic phase was discarded. The aqueous phase was acidified with 4 M hydrochloric acid solution to a pH of about 1, and then extracted with ethyl acetate (100 mL 4). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain No.29 (2R)-2-(tert-butoxycarbonylamino)propanoic acid (17B) as colorless oily substance (21.2 g, yield: 100%). MS m/z =212.1 [M+Na]+; 1HNMR (400 MHz, DMSO-d6) δ 12.34 (br, 1H), 7.05 (d, 1H), 3.98-3.87 (m, 1H), 1.38 (s, 9H), 1.22 (d, 3H).
98% With sodium hydroxide In tetrahydrofuran; water at 0 - 30℃; for 4.5h; 5.1 Step 1 (2R)-2-(tert-butoxycarbonylamino)propionicacid (2R) -2-aminopropionic acid (10 g, 0.11 mol) was dissolved in water (100 mL) at room temperature. Tetrahydrofuran (50 mL) and sodium hydroxide solid (4.9 g, 0.12 mol) were added, then cooled to 0 . Boc anhydride (27 mL, 0.12 mol) was added. The mixture was heated to room temperature and stirred for 4.5 h. The organic solvent was removed by concentration, and the aqueous phase was adjusted pH to 3 with 1 M hydrochloric acid. The mixture was extracted with ethyl acetate (150 mL× 2) . The organic phase was washed with saturated salt water (100 mL) , dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound as colorless oil (21 g, 98%) .
92% With triethylamine; sodium hydroxide In tetrahydrofuran; water at 20℃; for 10.5h; 1.2 (2)N-tert-butoxycarbonyl-D-alanine5Preparation Add 50 mmol of D-alanine and 100 mmol of sodium hydroxide to the mixed solution (10 ml THF/25 ml H 2 O).Triethylamine 60mmol,Take 50 mmol of di-tert-butyl dicarbonate and dissolve it in 15 ml of THF under ice bath.Slowly adding the above mixed solution with a constant pressure dropping funnel,After reacting for 30 minutes, the reaction was carried out to room temperature for about 10 hours.It was cooled to 0 ° C with an ice bath, and the pH was adjusted to 2 with 2 mol/L hydrochloric acid, and the mixture was extracted three times with ethyl acetate, 20 ml each time.The organic phases were combined and washed three times with saturated brine.20 ml each time, dry with an appropriate amount of anhydrous Na2SO4, and filter.Evaporating the organic solvent to give an oil.Add a small amount of petroleum ether and stir quickly until a large amount of solids appears.Filtered to a white solid. Yield 92%,
90% With sodium hydroxide In 1,4-dioxane; water for 20h; Ambient temperature;
90.9% With triethylamine In tetrahydrofuran; water at 0 - 20℃; 3.1.2. N-tert. Butoxycarbonyl-D-alanine (6a) To a solution of compound D-alanine (6.23 g, 70 mmol) and triethylamine (11.76 ml, 84mmol) in 40 ml H2O and 20 ml tetrahydrofuran, was added dropwise a solution of 15.28 g(70 mmol) di-tert-butyl dicarbonate in 20 ml tetrahydrofuran at 0 °C. The reaction mixturewas stirred for 0.5 h at 0 °C, then was reacted overnight at room temperature keeping pH 8-9.After cooling to 0 °C the mixture was acidified to pH 2-3 by the dropwise addition of 2 mol/l HCl solution and extracted with ethyl acetate. The organic phase was washedwith saturated brine and dried over anhydrous MgSO4 and concentrated with a rotaryevaporator to get the colorless oil which was stirred in petroleum ether. The white solidwas filtered as the title compound. Yield: 90.9 %; mp: 80.5-81.3 °C.
87% With sodium hydroxide In 1,4-dioxane; water at 5 - 20℃; for 72h;
82%
75% With triethylamine In 1,4-dioxane; water at 20℃;
74% With sodium carbonate In tetrahydrofuran; water at 0 - 20℃; for 48h;
73% With sodium hydroxide In tetrahydrofuran; water at 20℃; for 3h; 1.1 Step 1 (2R)-2-[(tert-butoxy)carbonyl]amino}propanoic acid (1b) D-alanine 1a (9.0 g, 0.10 mol) was dissolved in tetrahydrofuran (100 mL)a mixed solution with 10% aqueous sodium hydroxide solution (100 mL),Di-tert-butyl dicarbonate (25 mL, 0.11 mol) was added dropwise.The reaction was carried out for 3 hours at room temperature.Extracted with ethyl acetate (100 mL×2), the aqueous phase was adjusted to pH 2 with 4mol/L hydrochloric acid, and then extracted with dichloromethane/methanol (v/v=10/1, 100mL×2).The combined organic phases were dried over anhydrous sodiumThe title compound 1b was obtained as a white solid (14 g, yield 73%).Can be used directly in the next reaction.
With sodium hydroxide In <i>tert</i>-butyl alcohol for 12h; Ambient temperature;
With sodium hydroxide In tetrahydrofuran at 20℃; for 18h;
With sodium hydroxide In 1,4-dioxane at 0℃;
With sodium hydroxide In water; <i>tert</i>-butyl alcohol at 20℃;
Stage #1: D-Alanine; di-<i>tert</i>-butyl dicarbonate With potassium hydroxide In 1,4-dioxane; water at 20℃; for 12h; Stage #2: With sodium hydrogen sulfate In water; ethyl acetate
Stage #1: D-Alanine With sodium hydrogencarbonate In tetrahydrofuran; water for 0.25h; Stage #2: di-<i>tert</i>-butyl dicarbonate In tetrahydrofuran; water at 20℃; for 4h; Intermediate 30To a solution of D-alanine (4.45 g, 50 mmol) in THF (100 mL) and water (50 mL) was added a solution of NaHC03 (4.2 g, 50 mmol) in water (30 mL). After stirring for 15 minutes, a solution ofBoc-anhydride (16.35 g, 75 mmol) in THF (20 mL) was added and the mixture was stirred at room temperature for 4 hours. The solvent was evaporated and 2N HCI was used to adjust the pH=3-4.The mixture was extracted with ethyl actetate (3 times 200 mL) and the combined ethyl acetate layers were washed with brine (50 mL), dried and concentrated. The residue was recrystallized with ethyl acetate/hexane to afford the title compound as a white solid (5 g).HNMR (DMSO-d6): δ ppm 12.38 (1 H, s), 7.1 1 - 7.09 (1 H, d), 3.94 - 3.88 (1 H, m), 1.38 (9H, s), 1.22- 1.21 (3H, d).
With potassium hydroxide In 1,4-dioxane; water at 25℃; for 12h;
1.78 g Stage #1: D-Alanine; di-<i>tert</i>-butyl dicarbonate With potassium carbonate In methanol; water at 0 - 20℃; for 23.0833h; Stage #2: With citric acid In methanol; water 81a Intermediate 81 a: (R)-2-tert-butoxycarbonylamino-propionic acid To a suspension of D-alanine (1g, 1 1.22 mmol) in water (5.6 mL)/MeOH (2.80 mL) (2:1 ) K2C03 (1.55 g, 1 1.22 mmol) was added at 0-5°C, followed by a solution of Boc20 (2.61 mL, 1 1.22 mmol) in MeOH (2.80 mL) over 5 min. The resulting suspension was stirred for 23 h at rt. The reaction mixture was poured into water and acidified to pH= 3 with aqueous citric acid solution. The white cloudy solution was extracted with DCM (3x). Organic layers were combined, washed with brine, dried over MgS04, filtered and the solvent removed to yield 1.78 g, 9.43 mmol (R)-2- tert-butoxycarbonylamino-propionic acid.1H NMR (400 MHz, DMSO-c 6) δ ppm: 12.14 - 12.63 (m, 1 H), 6.97 - 7.19 (m, 1 H), 3.76 - 4.00 (m, 1 H), 1.38 (s, 9 H), 1.22 (d, J=7.09 Hz, 3 H).
With sodium hydroxide In tetrahydrofuran; water at 20℃; for 0.5h; 184 (R)-2-(tert-butoxycarbonylamino)propanoic acid (2): To a stirring solution of (R)-2-aminopropanoic acid SM1 (0.2 g, 2.25 mmol) in THF (10 mL) was added (Boc)20 (0.58 g, 2.7 mmol) and 10% NaOH aq (10 mL), the mixture was stirred at room temperature for 30 mins. The solvent was removed out in vacuo, the residue was diluted with brine and extracted with EtOAc. Combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain cmde product as an off-white solid, which was useddirectly for subsequent step. ‘HNMR (300 MHz, DMSO-d6): 12.44 (s, ‘H), 7.11 (s, 1H), 3.91 (m, 1H), 1.47 (d, J = 3.0 Hz, 3H), 1.37 (s, 9H).
With sodium hydroxide In water at 0 - 20℃; 1 Example 1 Preparation of compound (VIII) 50 g of D-alanine, 52 g of sodium hydroxide and about 40 mL of water were added to a 1000 mL single-necked flask, and about 150 g of di-tert-butyl dicarbonate was added thereto at 0 ± 10 ° C. After completion of the dropwise addition, the mixture was stirred at room temperature overnight, Methyl-N-methoxyhydrochloride, 130 g of 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl) After the addition, the mixture was stirred overnight at room temperature, and the reaction mixture was extracted with methylene chloride. The dichloromethane was washed once more with water, and the solvent was evaporated to give compound (VIII).
In chloroform
9.6 g With potassium hydroxide In tetrahydrofuran; water 2.1 Ν- (tert-butoxycarbonyl) -D-alanine (8a) (50 mmol) of D-alanine, 3.8 g (55 mmol) of potassium hydroxide and 13.0 g (55 mmol) of di-tert-butyl carbonate were suspended in a mixed solvent of water (200 mL) and THF (20 mL) Followed by stirring to give 9.6 g of N-Boc-D-alanine as a white solid which was used directly in the next esterification reaction without purification.
5.07 g Stage #1: D-Alanine With sodium hydroxide In water at 26℃; for 0.166667h; Stage #2: di-<i>tert</i>-butyl dicarbonate In water at 26℃; for 12h; 12 Synthesis of N-Boc-D-alanine compound 8, the reaction formula is: D-alanine (2.5 g, 27.8 mmol) was added to a dry flask.Distilled water (14 mL) and 1 M aqueous sodium hydroxide (139 mL) were added.After stirring at 26 ° C for 10 min, (Boc) 2 O (12.12 g, 55.6 mmol) was added thereto.The reaction was carried out at 26 ° C for 12 hours, and the reaction compound was lowered to 0 ° C.After adding 3M hydrochloric acid to adjust pH 2, the reaction mixture was diluted with 50 mL of ethyl acetate, and then the mixture was extracted with ethyl acetate three times, 70 mL each time, and the organic phase was combined.Dry over anhydrous sodium sulfate. The solvent is distilled off to obtain N-Boc-D-alanine 8,White solid 5.07 g.
Stage #1: D-Alanine With sodium carbonate In 1,4-dioxane; water Stage #2: di-<i>tert</i>-butyl dicarbonate In 1,4-dioxane; water for 18h; General procedure for the preparation of amino acidderivatives General procedure: The amino acid derivatives were prepared employinga methodology developed by our research group.19Initially, the coupling between the tert-butyloxycarbonyl(Boc) protecting group and amino acids (L-alanine,D,L-alanine, D-alanine, L-valine, L-leucine, L-isoleucineor L-phenylalanine, 1.0 mmol) was done by adding toa solution of 1,4-dioxane/water (40:60 v/v) the aminoacid and 50 mg of Na2CO3. The mixture was stirred untilcomplete dissolution and then Boc2O (1.5 mmol) wasadded. The reaction was kept at magnetic stirring for 18 hand then purified employing literature protocols. For the amide bond formation, the previously preparedBoc amino acids (1.0 mmol) were transferred to a famedriedglassware vial with dichloromethane (5.0 mL) andthen EDC (3-dimethylaminopropyl)-N-ethylcarbodiimide)hydrochloride (1.1 mmol) was added. The reaction stirredat 0 °C for 30 min, and then washed twice with distilledwater. The organic layer was immediately transferred toa vial with the amine nucleophile (2.0 mmol) and the(±)-camphorsulfonic acid organocatalyst (0.1 mmol,10 mol%). After 24 h the dichloromethane was removedand the desired compounds purified by recrystallization,liquid-liquid extraction or column chromatography.Boc deprotection of two of the previously preparedproducts was carried out following literature protocols,21in which the derivatives (1 mmol) and trifluoroacetic acid(22 mmol) were added in dichloromethane (5 mL) and keptunder magnetic stirring for 3 h, affording the salts 33 and34 after solvent removal.

Reference: [1]Current Patent Assignee: HAISCO PHARMACEUTICAL GROUP CO., LTD. - EP3656782, 2020, A1 Location in patent: Paragraph 0228
[2]Current Patent Assignee: NORTH &amp; SOUTH BROTHER PHARMACY INVESTMENT COMPANY LTD; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD - WO2019/144864, 2019, A1 Location in patent: Paragraph 00227; 00283
[3]Current Patent Assignee: NANCHANG UNIVERSITY - CN108148017, 2018, A Location in patent: Paragraph 0037; 0038
[4]Schwyzer; Do; Eberle; Fauchere [Helvetica Chimica Acta, 1981, vol. 64, # 7, p. 2078 - 2083]
[5]Gao, Min; He, Junhua; Xu, Weidong; Lai, Xiaoping; Liu, Fen; Tu, Guogang [Pharmazie, 2018, vol. 73, # 3, p. 123 - 127]
[6]Kokan, Zoran; Perić, Berislav; Vazdar, Mario; Marinić, Željko; Vikić-Topić, Dražen; Meštrović, Ernest; Kirin, Srećko I. [Chemical Communications, 2017, vol. 53, # 12, p. 1945 - 1948]
[7]Wolf; Pfander [Helvetica Chimica Acta, 1986, vol. 69, # 6, p. 1498 - 1504]
[8]Gao, Guangzheng; Sanda, Fumio; Masuda, Toshio [Macromolecules, 2003, vol. 36, # 11, p. 3938 - 3943]
[9]Mayer; Wimmer; Dillon-Carter; Partilla; Burchardt; Mihovilovic; Baumann; Sitte [British Journal of Pharmacology, 2016, p. 2657 - 2668]
[10]Current Patent Assignee: SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD - CN108341752, 2018, A Location in patent: Paragraph 0317; 0319; 0320; 0321
[11]Lucet, Denis; Le Gall, Thierry; Mioskowski, Charles; Ploux, Olivier; Marquet, Andree [Tetrahedron Asymmetry, 1996, vol. 7, # 4, p. 985 - 988]
[12]Pastor, Isidro M.; Vaestilae, Patrik; Adolfsson, Hans [Chemistry - A European Journal, 2003, vol. 9, # 17, p. 4031 - 4045]
[13]Jakopin, Žiga; Roškar, Robert; Dolenc, Marija Sollner [Tetrahedron Letters, 2007, vol. 48, # 8, p. 1465 - 1468]
[14]Location in patent: experimental part Yan, Jincan; Wang, Lei [Synthesis, 2008, # 13, p. 2065 - 2072]
[15]Location in patent: experimental part Schwarz, Stefan; Csuk, René [Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 21, p. 7458 - 7474]
[16]Current Patent Assignee: AUTIFONY THERAPEUTICS LIMITED - WO2011/69951, 2011, A1 Location in patent: Page/Page column 50
[17]Csuk, Rene; Schwarz, Stefan; Siewert, Bianka; Kluge, Ralph; Stroehl, Dieter [Zeitschrift fur Naturforschung, B: Chemical Sciences, 2012, vol. 67, # 7, p. 731 - 746]
[18]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2013/8162, 2013, A1 Location in patent: Page/Page column 93
[19]Current Patent Assignee: ABBVIE INC - WO2016/44770, 2016, A1 Location in patent: Page/Page column 698
[20]Current Patent Assignee: RUYUAN YAO AUTONOMOUS COUNTY DAZHONG DRUG TRADING - CN105503826, 2016, A Location in patent: Paragraph 0046; 0047; 0048
[21]Pidugu, Vijaya Rao; Yarla, Nagendra Sastry; Pedada, Srinivasa Rao; Kalle, Arunasree M.; Satya, A. Krishna [Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 21, p. 5611 - 5617]
[22]Current Patent Assignee: YANG, XUECONG; ZHAO, LEI; LIU, JIANG; HUANG, XINQUAN - CN106543253, 2017, A Location in patent: Paragraph 0092-0095
[23]Current Patent Assignee: LANZHOU UNIVERSITY - CN108690005, 2018, A Location in patent: Paragraph 0026; 0027
[24]de Castro, Pedro P.; Siqueira, Raoni P.; Conforte, Luiza; Franco, Chris H.J.; Bressan, Gustavo C.; Amarante, Giovanni W. [Journal of the Brazilian Chemical Society, 2020, vol. 31, # 1, p. 193 - 200]
  • 2
  • [ 15761-39-4 ]
  • [ 13139-15-6 ]
  • [ 7764-95-6 ]
  • [ 13836-37-8 ]
  • [ 120287-85-6 ]
YieldReaction ConditionsOperation in experiment
Multistep reaction;
  • 3
  • [ 7764-95-6 ]
  • [ 117771-39-8 ]
  • [ 1149752-64-6 ]
YieldReaction ConditionsOperation in experiment
80% Stage #1: Boc-(R)-Ala With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In water; dimethyl sulfoxide at 20 - 25℃; for 0.333333h; Stage #2: acetamide oxime In water; dimethyl sulfoxide at 23 - 102℃; for 1.08333h; 46.46.A Example 46A
(R)-tert-butyl (1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)carbamate
A mixture of N-(tert-butoxycarbonyl)-D-alanine (13.7 g, 72.4 mmol), 1-hydroxybenzotriazole hydrate (wetted with 20 weight % water, 14.7 g, 87 mmol), and dimethyl sulfoxide (69 mL) was stirred at ambient temperature (water bath) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (16.0 g, 83 mmol) was added (exotherm from 20° C. to 25° C.). After 20 minutes (nearly homogeneous), N-hydroxyacetamidine (6.44 g, 87 mmol) (exotherm from 23° C. to 30° C.) was added followed by stirring for 5 minutes. The clear solution was then heated to 98-102° C. for 1 hour. The mixture was allowed to cool to <25° C., was partitioned between water (70 mL) and cyclopentyl methyl ether (CPME) (140 mL), and the layers were separated. The aqueous layer was extracted with CPME (70 mL+28 mL). The combined organic layers were washed with brine (28 mL), saturated aqueous NaHCO3 (2*70 mL) and again with brine (28 mL). The NaHCO3/brine aqueous layer was again extracted with CPME (70 mL), and the combined organic fractions were dried over anhydrous Na2SO4 and concentrated under reduced pressure to 35.4 g total mass (˜26 mL CPME based on assumed 80% yield in line with previous experiments), giving a solution of the titled compound used without purification in the next step. Chiral HPLC (Daicel CHIRALCEL OJ-3 column, 1% isopropyl acetate/heptanes isocratic, 1 mL/minute, detection at 210 nm) of this material showed 98% ee. MS (DCI) m/z 245 [M+NH4]+.
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In 1,4-dioxane; N,N-dimethyl-formamide at 60 - 100℃; for 20h; 6.A INTERMEDIATE 6; riRVl-r3-Methyl-1.2.4-oxadia2θl-5-yl)ethanamine; Step A: tert-Butyl [(lR)-l-(3-methyl-L2.4-oxadiazol-5-yDethyllcarbamate; To a solution of N-(tert-butoxycarbonyl)-D-alanine (20 g, 106 mmol), acetamide oxime (17.3 g, 234 mmol) in 120 mL of 1 ,4-dioxane and 30 mL of N, N-dimethylformamide were added EDC (44.8 g, 234 mmol). The mixture was heated at 60 °C for 4 h then at 100 °C for 16 h. After cooling to ambient temperature, 300 mL of ethyl acetate was added. The mixture was washed with aqueous saturated sodium bicarbonate (2x). The combined organic extracts were dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (100% dichloromethane - > 90% dichloromethane/ methanol) to give pure tert-butyl [(lR)-l-(3-methyl-l,2,4-oxadiazol-5-yl)ethyl]carbamate (6.0 g). MS 172.1 ((M-f- butyl+H)+l).
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In 1,4-dioxane; N,N-dimethyl-formamide at 60 - 100℃; for 20h; 6.A INTERMEDIATE 6; ( 1 RV 1 -(3-methyl- 1 ,2,4-oxadiazol-5-yl)ethanamine; Step A: tert-butyl |"αR)-l-(3-methyl-L2.4-oxadiazol-5-vϖethyl]carbaniate; To a solution of N-(tert-butoxycarbonyl)-D-alanine (20 g, 106 mmol), acetamide oxime (17.3 g, 234 mmol) in 120 mL of 1 ,4-dioxane and 30 mL of N, jV-dimethylformamide were added EDC (44.8 g, 234 mmol). The mixture was heated at 60 0C for 4 h and at 100 0C for 16 h. After cooling to ambient temperature, 300 mL of ethyl acetate was added into the reaction. The organic layer was washed by saturated sodium bicarbonate (2x). The organic were dried over magnesium sulfate, filtered and concentrated. The residue was purified by 0-10% methanol/dichloromethane gradient on silica column to give pure tert-butyl [( IR)-I -(3-methyl- l,2,4-oxadiazol-5-yl)ethyl]carbamate (6.0 g). MS 172.1 ((M-t-Butyl+H)+l).
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In 1,4-dioxane; N,N-dimethyl-formamide at 60 - 100℃; for 20h; 4.A To a solution of N-(ter*-butoxycarbonyl)-D-alanine (20 g, 106 mmol), acetamide oxime(17.3 g, 234 mmol) in 120 mL of 1,4-dioxane and 30 mL of N, N-dirnethylformarnide were added EDC (44.8 g, 234 mmol). The mixture was heated at 60 °C for 4 h then at 100 °C for 16 h. After cooling to ambient temperature, 300 mL of ethyl acetate was added. The mixture was washed with aqueous saturated sodium bicarbonate (2x). The combined organic extracts were dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (100% dichloromethane → 90% dichloromethane/ methanol) to give pure /erf-butyl [( IR)-I -(3-methyl- 1,2,4- oxadiazol-5-yl)ethyl]carbamate (6.0 g). MS 172.1 ((M-r-butyl+H)+l).
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In 1,4-dioxane; N,N-dimethyl-formamide at 60 - 100℃; for 20h; 4.A To a solution of iV~(te?t-butoxycarbonyl)-D-alanine (20 g, 106 mmol), acetamide oxime (17.3 g, 234 mmol) in 120 mL of 1,4-dioxane and 30 niL of N, jV-dimethylformamide were added EDC (44.8 g, 234 mmol). The mixture was heated at 60 °C for 4 h then at 100 °C for 16 h. After cooling to ambient temperature., 300 mL of ethyl acetate was added. The mixture was washed with aqueous saturated sodium bicarbonate (2x). The combined organic extracts were dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (100% dichloromethane → 90% dichloromethane/ methanol) to give pure tert-butyl [(I R)- 1-(3 -methyl- 1 ,2f4-oxadiazol-5-yl)ethyl] carbamate (6.0 g). MS 172.1 ((M-£- butyl+H)+l).
6 g With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In 1,4-dioxane; N,N-dimethyl-formamide at 60 - 100℃; for 20h; 4.A Step A: Step A: tert-Butyl[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]carbamate To a solution of N-(tert-butoxycarbonyl)-D-alanine (20 g, 106 mmol), acetamide oxime (17.3 g, 234 mmol) in 120 mL of 1,4-dioxane and 30 mL of N, N-dimethylformamide were added EDC (44.8 g, 234 mmol). The mixture was heated at 60 °C for 4 h then at 100 °C for 16 h. After cooling to ambient temperature, 300 mL of ethyl acetate was added. The mixture was washed with aqueous saturated sodium bicarbonate (2x). The combined organic extracts were dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (100% dichloromethane → 90% dichloromethane/ methanol) to give pure tert-butyl [(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]carbamate (6.0 g). MS 172.1 ((M-t-butyl carbamate+H)+1).

  • 4
  • [ 13734-41-3 ]
  • [ 13139-16-7 ]
  • [ 13139-15-6 ]
  • [ 15761-38-3 ]
  • [ 57294-38-9 ]
  • [ CAS Unavailable ]
  • [ 7764-95-6 ]
  • [ CAS Unavailable ]
  • [ 501-97-3 ]
  • [ 13734-34-4 ]
  • [ 15260-10-3 ]
  • [ 34306-42-8 ]
  • [ 13836-37-8 ]
  • [ 23680-31-1 ]
  • [ 73821-95-1 ]
  • [ 47689-67-8 ]
  • [ 6404-28-0 ]
  • [ 118554-00-0 ]
  • [ CAS Unavailable ]
YieldReaction ConditionsOperation in experiment
27 mg Stage #1: N-(tert-butoxycarbonyl)-4-aminobutanoic acid With N-ethyl-N,N-diisopropylamine; diisopropyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide for 1h; Stage #2: With trifluoroacetic acid In dichloromethane; N,N-dimethyl-formamide for 0.5h; Stage #3: t-Boc-L-valine; N-(tert-butyloxycarbonyl)-L-isoleucine; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-leucine; L-N-Boc-Ala; N-(tert-butoxycarbonyl)-4-aminobutanoic acid; N-tert-butyloxycarbonylasparagine; Boc-(R)-Ala; Boc-Gln-OH; 4-hydroxyphenylpropionic acid; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-phenylalanine; N-Boc-O-benzyl-L-threonine; Boc-Abu; Boc-Arg(Tos)-OH; BOC-O-benzyl-L-serine; Boc-Asp(O-cyclohexyl)-OH; (S)-3-[4-(2-Bromo-benzyloxycarbonyloxy)-phenyl]-2-tert-butoxycarbonylamino-propionic acid; Boc-Nle-OH; N-tert-butoxycarbonyl-N'-(2-chlorobenzyloxycarbonyl)-L-ornithine Further stages; 5 Example 5 Dat1-D-Ala2-Asp3-Ala4-Ile5-Phe6-Thr7-Asn8-Ser9-Tyr10-Arg11-Orn12-Var3-Leu14-Abu15-Gln16-Leu17-Ser18-Ala19-Arg20-Orn21-Leu22-Leu23-Gln24-Asp25-Ile26-Nle27-Ser28-Arg29-Gln-Gab30-NH2 (Peptide 29702) Dat1, D-Ala2, Orn12, Abu15, Orn21, Nle27, Gln-Gab30]hGHRH(1-30)-NH2. The synthesis is conducted in a stepwise manner using manual solid phase peptide synthesis equipment. Briefly, para-methylbenzhydrylamine (MBHA) resin (Bachem, King of Prussia, Pa.) (720 mg, 0.50 mmol) is pre-swollenin DCM and neutralized with 5% DIEA in DCM and washed according to the protocol described in Table I. The solution of Boc-Gab-OH (265 mg, 1.5 mmol) in DMF-DCM (1:1) is shaken with the neutralized resin and DIC (235 μL, 1.5 mmol) in a manual solid phase peptide synthesis apparatus for 1 hour. After the completion of the coupling reaction is proved by negative ninhydrin test, the deprotection and neutralization protocols described in Table 2 are performed in order to remove the Boc protecting group and prepare the peptide-resin for coupling of the next amino acid. The synthesis is continued and the peptide chain is built stepwise by coupling the following protected amino acids in the indicated order on the resin to obtain the desired peptide sequence: Boc-Gab-OH, Boc-Gln-OH, Boc-Arg(Tos)-OH, Boc-Ser(Bzl)-OH, Boc-Nle-OH, Boc-Ile-OH, Boc-Asp(OcHx)-OH, Boc-Gln-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Orn(2ClZ)-OH, Boc-Arg(Tos)-OH, Boc-Ala-OH, Boc-Ser(Bzl)-OH, Boc-Leu-OH, Boc-Gln-OH, Boc-Abu-OH, Boc-Leu-OH, Boc-Val-OH, Boc-Orn(2ClZ)-OH, Boc-Arg(Tos)-OH, Boc-Tyr(2BrZ)-OH, Boc-Ser(Bzl)-OH, Boc-Asn-OH, Boc-Thr(Bzl)-OH, Boc-Phe-OH, Boc-Ile-OH, Boc-Ala-OH, Boc-Asp(OcHx)-OH, Boc-D-Ala-OH, Dat-OH. These protected amino acid residues (also commonly available from Novabiochem, Advanced Chemtech, Bachem, and Peptides International) are represented above according to a well accepted convention. The suitable protecting group for the side chain functional group of particular amino acids appears in parentheses. The OH groups in the above formulae indicate that the carboxyl terminus of each residue is free. The protected amino acids (1.5 mmol each) are coupled with DIC (235 μL, 1.5 mmol) with the exceptions of Boc-Asn-OH and Boc-Gln-OH which are coupled with their preformed HOBt esters. In order to cleave the peptide from the resin and deprotect it, a portion of 250 mg of the dried peptide resin is stirred with 0.5 mL m-cresol and 5 mL hydrogen fluoride (HF) at 0° C. for 2 hours. After evaporation of the HF under a stream of nitrogen and in vacuo, the residue is washed with dry diethyl ether and ethyl acetate. The cleaved and deprotected peptide is dissolved in 50% acetic acid and separated from the resin by filtration. After dilution with water and lyophilization, 109 mg crude product is obtained. The crude peptide is checked by analytical HPLC using a Hewlett-Packard Model HP-1090 liquid chromatograph equipped with a Supelco Discovery HS C18 reversed-phase column (2.1 mm×5 cm, packed with C18 silica gel, 300 pore size, 3 μm particle size) (Supelco, Bellefonte, Pa.). Linear gradient elution (e.g., 40-70% B) is used with a solvent system consisting of (A) 0.1% aqueous TFA and (B) 0.1% TFA in 70% aqueous MeCN, and the flow rate is 0.2 mL/min. Purification is performed on a Beckman System Gold HPLC system (Beckman Coulter, Inc., Brea, Calif.) equipped with 127P solvent Module; UV-VIS Detector, model 166P; Computer workstation with CPU Monitor and printer, and 32-Karat software, version 3.0. 109 mg of crude peptide is dissolved in AcOH/H2O, stirred, filtered and applied on an XBridge Prep OBD reversed phase column (4.6×250 mm, packed with Ci8 silica gel, 300 A pore size, 5 μm particle size) (Waters Co., Milford, Mass.). The column is eluted with a solvent system described above in a linear gradient mode (e.g., 40-60% B in 120 min); flow rate 12 mL/min. The eluent is monitored at 220 nm, and fractions are examined by analytical HPLC. Fractions with purity higher than 95% are pooled and lyophilized to give 27 mg pure product. The analytical HPLC is carried out on a Supeico Discovery C18 reversed-phase column described above using isocratic elution with a solvent system described above with a flow rate of 0.2 mL/min. The peaks are monitored at 220 and 280 nm. The product is judged to be substantially (>95%) pure by analytical HPLC. Molecular mass is checked by electrospray mass spectrometry, and the expected amino acid composition is confirmed by amino acid analysis.
  • 5
  • [ 13734-41-3 ]
  • [ 13139-16-7 ]
  • [ 13139-15-6 ]
  • [ 15761-38-3 ]
  • [ 7536-55-2 ]
  • Boc-(R)-Ala [ No CAS ]
  • [ 13726-85-7 ]
  • [ 13734-34-4 ]
  • [ 15260-10-3 ]
  • [ 34306-42-8 ]
  • [ 13836-37-8 ]
  • [ 93288-03-0 ]
  • [ 23680-31-1 ]
  • [ 73821-95-1 ]
  • [ 47689-67-8 ]
  • [ 6404-28-0 ]
  • [ 144183-31-3 ]
  • N-tert-butoxycarbonyl-N'-(2-chlorobenzyloxycarbonyl)-L-ornithine [ No CAS ]
  • Dat-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Orn-Val-Leu-Abu-Gln-Leu-Ser-Ala-Arg-Orn-Leu-Leu-Gln-Asp-Ile-Nle-Asp-Arg-Amc-NH2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
28 mg Stage #1: N-(8-hydroxyoctyl)carbamic acid tert-butyl ester With N-ethyl-N,N-diisopropylamine; diisopropyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide for 1h; Stage #2: With trifluoroacetic acid In dichloromethane; N,N-dimethyl-formamide for 0.5h; Stage #3: t-Boc-L-valine; N-(tert-butyloxycarbonyl)-L-isoleucine; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-leucine; L-N-Boc-Ala; N-tert-butyloxycarbonylasparagine; Boc-(R)-Ala; Boc-Gln-OH; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-phenylalanine; N-Boc-O-benzyl-L-threonine; Boc-Abu; Boc-Arg(Tos)-OH; Boc-N-Me-Tyr(2-BrZ)-OH; BOC-O-benzyl-L-serine; Boc-Asp(O-cyclohexyl)-OH; (S)-3-[4-(2-Bromo-benzyloxycarbonyloxy)-phenyl]-2-tert-butoxycarbonylamino-propionic acid; Boc-Nle-OH; N-tert-butoxycarbonyl-N'-(2-chlorobenzyloxycarbonyl)-L-ornithine Further stages; 2 Example 2 Dat1-D-Ala2-Asp3-Ala4-Ile5-Phe6-Thr7-Asn8-Ser9-Tyr10-Arg11-Orn12-Val13-Leu14-Abu15-Gln16-Leu17-Ser18-Ala19-Arg20-Orn21-Leu22-Leu23-Gln24-Asp25-Ile26-Nle27-Asp28-Arg29-Amc30-NH2 (Peptide 21300)[Dat1, D-Ala2, Orn12, Abu15, Orn21, Nle27, Asp28, Amc30]hGHRH(1-30)NH2. The synthesis is conducted in a stepwise manner using manual solid phase peptide synthesis equipment. Briefly, para-methylbenzhydrylamine (MBHA) resin (100-200 mesh, 1% DVB, 0.7 mmol/g, Advanced Chemtech, Louisville, Ky.) (350 mg, 0.50 mmol) is neutralized with 5% DIEA in DCM and washed according to the protocol described in Table 2. The solution of Boc-Amc-OH (390 mg, 1.5 mmol) in DMF-DCM (1:1) is shaken with the neutralized MBHA resin and DIC (235 μl, 1.5 mmol) in a manual solid phase peptide synthesis apparatus for 1 hour. After the completion of the coupling reaction is proved by negative ninhydrin test, the deprotection and neutralization protocols described in Table 2 are performed in order to remove the Boc protecting group and prepare the peptide-resin for coupling of the next amino acid. The synthesis is continued and the peptide chain is built stepwise by coupling the following protected amino acids in the indicated order on the resin to obtain the desired peptide sequence: Boc-Arg(Tos)-OH, Boc-Asp(OcHx)-OH, Boc-Nle-OH, Boc-Ile-OH, Boc-Asp(OcHx)-OH, Boc-Gln-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Orn(2ClZ)-OH, Boc-Arg(Tos)-OH, Boc-Ala-OH, Boc-Ser(Bzl)-OH, Boc-Leu-OH, Boc-Gln-OH, Boc-Abu-OH, Boc-Leu-OH, Boc-Val-OH, Boc-Orn(2ClZ)-OH, Boc-Arg(Tos)-OH, Boc-Tyr(2BrZ)-OH, Boc-Ser(Bzl)-OH, Boc-Asn-OH, Boc-Thr(Bzl)-OH, Boc-Phe-OH, Boc-Ile-OH, Boc-Ala-OH, Boc-Asp(OcHx)-OH, Boc-D-Ala-OH, Boc-N-Me-Tyr(2BrZ)-OH. These protected amino acid residues (also commonly available from Novabiochem, Advanced Chemtech, Bachem, and Peptides International) are represented above according to a well accepted convention. The suitable protecting group for the side chain functional group of particular amino acids appears in parentheses. The OH groups in the above formulae indicate that the carboxyl terminus of each residue is free. The protected amino acids (1.5 mmol each) are coupled with DIC (235 μL, 1.5 mmol) with the exceptions of Boc-Asn-OH and Boc-Gln-OH which are coupled with their preformed HOBt esters. In order to cleave the peptide from the resin and deprotect it, a portion of 250 mg of the dried peptide resin is stirred with 0.5 mL m-cresol and 5 mL hydrogen fluoride (HF) at 0° C. for 2 hours. After evaporation of the HF under a stream of nitrogen and in vacuo, the residue is washed with dry diethyl ether and ethyl acetate. The cleaved and deprotected peptide is dissolved in 50% acetic acid and separated from the resin by filtration. After dilution with water and lyophilization, 130 mg crude product is obtained. The crude peptide is checked by analytical HPLC using a Hewlett-Packard Model HP-1090 liquid chromatograph equipped with a Supelco Discovery HS C18 reversed-phase column (2.1 mm×5 cm, packed with C18 silica gel, 300 A pore size, 3 μm particle size) (Supelco, Bellefonte, Pa.). Linear gradient elution (e.g., 40-70% B) is used with a solvent system consisting of (A) 0.1% aqueous TFA and (B) 0.1% TFA in 70% aqueous MeCN, and the flow rate is 0.2 mL/min. Purification is performed on a Beckman System Gold HPLC system (Beckman Coulter, Inc., Brea, Calif.) equipped with 127P solvent Module; UV-VIS Detector, model 166P; Computer workstation with CPU Monitor and printer, and 32-Karat software, version 3.0. 130 mg of crude peptide is dissolved in AcOH/H2O, stirred, filtered and applied on an XBridge Prep OBD reversed phase column (4.6×250 mm, packed with C18 silica gel, 300 A pore size, 5 μm particle size) (Waters Co., Milford, Mass.). The column is eluted with a solvent system described above in a linear gradient mode (e.g., 40-60% B in 120 min); flow rate 12 mL/min. The eluent is monitored at 220 nm, and fractions are examined by analytical HPLC. Fractions with purity higher than 95% are pooled and lyophilized to give 28 mg pure product. The analytical HPLC is carried out on a Supelco Discovery C18 reversed-phase column described above using isocratic elution with a solvent system described above with a flow rate of 0.2 mL/min. The peaks are monitored at 220 and 280 nm. The product is judged to be substantially (>95%) pure by analytical HPLC. Molecular mass is checked by electrospray mass spectrometry, and the expected amino acid composition is confirmed by amino acid analysis.
  • 6
  • [ 13734-41-3 ]
  • [ 13139-16-7 ]
  • [ 13139-15-6 ]
  • [ 15761-38-3 ]
  • [ CAS Unavailable ]
  • [ 7764-95-6 ]
  • [ CAS Unavailable ]
  • [ 13734-34-4 ]
  • [ 15260-10-3 ]
  • [ 34306-42-8 ]
  • [ 13836-37-8 ]
  • [ 93288-03-0 ]
  • [ 27687-14-5 ]
  • [ 23680-31-1 ]
  • [ 73821-95-1 ]
  • [ 47689-67-8 ]
  • [ 6404-28-0 ]
  • [ 118554-00-0 ]
  • [ CAS Unavailable ]
YieldReaction ConditionsOperation in experiment
Stage #1: trans 4-(tert-butyloxycarbonylamino)methylcyclohexanecarboxylic acid With dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide for 1h; Stage #2: With trifluoroacetic acid In dichloromethane for 0.5h; Stage #3: t-Boc-L-valine; N-(tert-butyloxycarbonyl)-L-isoleucine; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-leucine; L-N-Boc-Ala; N-tert-butyloxycarbonylasparagine; Boc-(R)-Ala; Boc-Gln-OH; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-phenylalanine; N-Boc-O-benzyl-L-threonine; Boc-Abu; Boc-Arg(Tos)-OH; Boc-N-Me-Tyr(2-BrZ)-OH; BOC-O-benzyl-L-serine; Boc-Asp(O-cyclohexyl)-OH; (S)-3-[4-(2-Bromo-benzyloxycarbonyloxy)-phenyl]-2-tert-butoxycarbonylamino-propionic acid; Boc-Nle-OH; N-tert-butoxycarbonyl-N'-(2-chlorobenzyloxycarbonyl)-L-ornithine Further stages; II The synthesis is conducted in a stepwise manner using manual solid phase peptide synthesis equipment. Briefly, para-methylbenzhydrylamine (MBHA) resin (100-200 mesh, 1% DVB, 0.7 mmol/g, Advanced Chemtech, Louisville, Ky.) (350 mg, 0.50 mmol) is neutralized with 5% DIEA in DCM and washed according to the protocol described in Table 2. The solution of Boc-Amc-OH (390 mg, 1.5 mmol) in DMF-DCM (1:1) is shaken with the neutralized MBHA resin and DIC (235 μL, 1.5 mmol) in a manual solid phase peptide synthesis apparatus for 1 hour. After the completion of the coupling reaction is proved by negative ninhydrin test, the deprotection and neutralization protocols described in Table 2 are performed in order to remove the Boc protecting group and prepare the peptide-resin for coupling of the next amino acid. The synthesis is continued and the peptide chain is built stepwise by coupling the following protected amino acids in the indicated order on the resin to obtain the desired peptide sequence: Boc-Arg(Tos)-OH, Boc-Asp(OcHx)-OH, Boc-Nle-OH, Boc-Ile-OH, Boc-Asp(OcHx)-OH, Boc-Gln-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Orn(2CIZ)-OH, Boc-Arg(Tos)-OH, Boc-Ala-OH, Boc-Ser(Bzl)-OH, Boc-Leu-OH, Boc-Gln-OH, Boc-Abu-OH, Boc-Leu-OH, Boc-Val-OH, Boc-Orn(2CIZ)-OH, Boc-Arg(Tos)-OH, Boc-Tyr(2BrZ)-OH, Boc-Ser(Bzl)-OH, Boc-Asn-OH, Boc-Thr(Bzl)-OH, Boc-Phe-OH, Boc-Ile-OH, Boc-Ala-OH, Boc-Asp(OcHx)-OH, Boc-D-Ala-OH, Boc-N-Me-Tyr(2BrZ)-OH. These protected amino acid residues (also commonly available from Novabiochem, Advanced Chemtech, Bachem, and Peptides International) are represented above according to a well accepted convention. The suitable protecting group for the side chain functional group of particular amino acids appears in parentheses. The OH groups in the above formulae indicate that the carboxyl terminus of each residue is free. The protected amino acids (1.5 mmol each) are coupled with DIC (235 μL, 1.5 mmol) with the exceptions of Boc-Asn-OH and Boc-Gln-OH which are coupled with their preformed HOBt esters. (0188) In order to cleave the peptide from the resin and deprotect it, a portion of 250 mg of the dried peptide resin is stirred with 0.5 mL m-cresol and 5 mL hydrogen fluoride (HF) at 0-° C. for 2 hours. After evaporation of the HF under a stream of nitrogen and in vacuo, the residue is washed with dry diethyl ether and ethyl acetate. The cleaved and deprotected peptide is dissolved in 50% acetic acid and separated from the resin by filtration. After dilution with water and lyophilization, 130 mg crude product is obtained. (0189) The crude peptide is checked by analytical HPLC using a Hewlett-Packard Model HP-1090 liquid chromatograph equipped with a Supelco Discovery HS C18 reversed-phase column (2.1 mm×5 cm, packed with C18 silica gel, 300 pore size, 3 μm particle size) (Supelco, Bellefonte, Pa.). Linear gradient elution (e.g., 40-70% B) is used with a solvent system consisting of (A) 0.1% aqueous TFA and (B) 0.1% TFA in 70% aqueous MeCN, and the flow rate is 0.2 mL/min. Purification is performed on a Beckman System Gold HPLC system (Beckman Coulter, Inc., Brea, Calif.) equipped with 127P solvent Module; UV-VIS Detector, model 166P; Computer workstation with CPU Monitor and printer, and 32-Karat software, version 3.0. 130 mg of crude peptide is dissolved in AcOH/H2O, stirred, filtered and applied on an XBridge Prep OBD reversed phase column (4.6×250 mm, packed with C18 silica gel, 300 pore size, 5 μm particle size) (Waters Co., Milford, Mass.). The column is eluted with a solvent system described above in a linear gradient mode (e.g., 40-60% B in 120 min); flow rate 12 mL/min. The eluent is monitored at 220 nm, and fractions are examined by analytical HPLC. Fractions with purity higher than 95% are pooled and lyophilized to give 28 mg pure product. The analytical HPLC is carried out on a Supelco Discovery C18 reversed-phase column described above using isocratic elution with a solvent system described above with a flow rate of 0.2 mL/min. The peaks are monitored at 220 and 280 nm. The product is judged to be substantially (>95%) pure by analytical HPLC. Molecular mass is checked by electrospray mass spectrometry, and the expected amino acid composition is confirmed by amino acid analysis.
  • 7
  • [ 13734-41-3 ]
  • [ 13139-16-7 ]
  • [ 13139-15-6 ]
  • [ 15761-38-3 ]
  • [ 57294-38-9 ]
  • [ CAS Unavailable ]
  • [ 7764-95-6 ]
  • [ CAS Unavailable ]
  • [ 501-97-3 ]
  • [ 13734-34-4 ]
  • [ 15260-10-3 ]
  • [ 34306-42-8 ]
  • [ 13836-37-8 ]
  • [ 23680-31-1 ]
  • [ 73821-95-1 ]
  • [ 47689-67-8 ]
  • [ 6404-28-0 ]
  • [ 118554-00-0 ]
  • [ CAS Unavailable ]
YieldReaction ConditionsOperation in experiment
Stage #1: N-(tert-butoxycarbonyl)-4-aminobutanoic acid With dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide for 1h; Stage #2: With trifluoroacetic acid In dichloromethane for 0.5h; Stage #3: t-Boc-L-valine; N-(tert-butyloxycarbonyl)-L-isoleucine; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-leucine; L-N-Boc-Ala; N-tert-butyloxycarbonylasparagine; Boc-(R)-Ala; Boc-Gln-OH; 4-hydroxyphenylpropionic acid; <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-phenylalanine; N-Boc-O-benzyl-L-threonine; Boc-Abu; Boc-Arg(Tos)-OH; BOC-O-benzyl-L-serine; Boc-Asp(O-cyclohexyl)-OH; (S)-3-[4-(2-Bromo-benzyloxycarbonyloxy)-phenyl]-2-tert-butoxycarbonylamino-propionic acid; Boc-Nle-OH; N-tert-butoxycarbonyl-N'-(2-chlorobenzyloxycarbonyl)-L-ornithine Further stages; V Dat1, D-Alu2, Orn12, Abu15, Orn21, Nle27, Gln-Gab30]hGH-RH(1-30)-NH2 (0319) The synthesis is conducted in a stepwise manner using manual solid phase peptide synthesis equipment. Briefly, para-methylbenzhydrylamine (MBHA) resin (Bachem, King of Prussia, Pa.) (720 mg, 0.50 mmol) is pre-swollen in DCM and neutralized with 5% DIEA in DCM and washed according to the protocol described in Table I. The solution of Boc-Gab-OH (265 mg, 1.5 mmol) in DMF-DCM (1:1) is shaken with the neutralized resin and DIC (235 μL, 1.5 mmol) in a manual solid phase peptide synthesis apparatus for 1 hour. After the completion of the coupling reaction is proved by negative ninhydrin test, the deprotection and neutralization protocols described in Table 2 are performed in order to remove the Boc protecting group and prepare the peptide-resin for coupling of the next amino acid. The synthesis is continued and the peptide chain is built stepwise by coupling the following protected amino acids in the indicated order on the resin to obtain the desired peptide sequence: Boc-Gab-OH, Boc-Gln-OH, Boc-Arg(Tos)-OH, Boc-Ser(Bzl)-OH, Boc-Nle-OH, Boc-Ile-OH, Boc-Asp(OcHx)-OH, Boc-Gln-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Orn(2CIZ)-OH, Boc-Arg(Tos)-OH, Boc-Ala-OH, Boc-Ser(Bzl)-OH, Boc-Leu-OH, Boc-Gln-OH, Boc-Abu-OH, Boc-Leu-OH, Boc-Val-OH, Boc-Orn(2CIZ)-OH, Boc-Arg(Tos)-OH, Boc-Tyr(2BrZ)-OH, Boc-Ser(Bzl)-OH, Boc-Asn-OH, Boc-Thr(Bzl)-OH, Boc-Phe-OH, Boc-Ile-OH, Boc-Ala-OH, Boc-Asp(OcHx)-OH, Boc-D-Ala-OH, Dat-OH. (0320) These protected amino acid residues (also commonly available from Novabiochem, Advanced Chemtech, Bachem, and Peptides International) are represented above according to a well accepted convention. The suitable protecting group for the side chain functional group of particular amino acids appears in parentheses. The OH groups in the above formulae indicate that the carboxyl terminus of each residue is free. (0321) The protected amino acids (1.5 mmol each) are coupled with DIC (235 μl, 1.5 mmol) with the exceptions of Boc-Asn-OH and Boc-Gln-OH which are coupled with their preformed HOBt esters. (0322) In order to cleave the peptide from the resin and deprotect it, a portion of 250 mg of the dried peptide resin is stirred with 0.5 mL m-cresol and 5 mL hydrogen fluoride (HF) at 0-° C. for 2 hours. After evaporation of the HF under a stream of nitrogen and in vacuo, the residue is washed with dry diethyl ether and ethyl acetate. The cleaved and deprotected peptide is dissolved in 50% acetic acid and separated from the resin by filtration. After dilution with water and lyophilization, 109 mg crude product is obtained. (0323) The crude peptide is checked by analytical HPLC using a Hewlett-Packard Model HP-1090 liquid chromatograph equipped with a Supelco Discovery HS C18 reversed-phase column (2.1 mm×5 cm, packed with C18 silica gel, 300 pore size, 3 μm particle size) (Supelco, Bellefonte, Pa.). Linear gradient elution (e.g., 40-70% B) is used with a solvent system consisting of (A) 0.1% aqueous TFA and (B) 0.1% TFA in 70% aqueous MeCN, and the flow rate is 0.2 mL/min. Purification is performed on a Beckman System Gold HPLC system (Beckman Coulter, Inc., Brea, Calif.) equipped with 127P solvent Module; UV-VIS Detector, model 166P; Computer workstation with CPU Monitor and printer, and 32-Karat software, version 3.0. 109 mg of crude peptide is dissolved in AcOH/H2O, stirred, filtered and applied on an XBridge Prep OBD reversed phase column (4.6×250 mm, packed with C18 silica gel, 300 pore size, 5 μm particle size) (Waters Co., Milford, Mass.). The column is eluted with a solvent system described above in a linear gradient mode (e.g., 40-60% B in 120 min); flow rate 12 mL/min. The eluent is monitored at 220 nm, and fractions are examined by analytical HPLC. Fractions with purity higher than 95% are pooled and lyophilized to give 27 mg pure product. The analytical HPLC is carried out on a Supelco Discovery C18 reversed-phase column described above using isocratic elution with a solvent system described above with a flow rate of 0.2 mL/min. The peaks are monitored at 220 and 280 nm. The product is judged to be substantially (>95%) pure by analytical HPLC. Molecular mass is checked by electrospray mass spectrometry, and the expected amino acid composition is confirmed by amino acid analysis.
  • 8
  • [ 3744-87-4 ]
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (R)-2-((tert-butoxycarbonyl)amino)propanoate [ No CAS ]
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 7764-95-6 ]

Amino Acid

Chemical Structure| 13726-84-6

[ 13726-84-6 ]

Boc-Glu(OtBu)-OH

Similarity: 0.80

Chemical Structure| 149794-10-5

[ 149794-10-5 ]

Boc-N-Ethylglycine

Similarity: 0.80

Chemical Structure| 34582-32-6

[ 34582-32-6 ]

Boc-Asp-OtBu

Similarity: 0.79

Chemical Structure|

[ ]

Similarity: 0.71

Chemical Structure| 71449-08-6

[ 71449-08-6 ]

Z-D-Asp(OtBu)-OH

Similarity: 0.66